ORPHA:492
Proliferating trichilemmal cyst
Publications
626
85th percentile
Trials
0
Interventional, condition-specific
Researchers
899
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare large, multinodular, usually benign, tumor that is generally located in the posterior part of the scalp in aged women (over 50 years). It first appears as a painless nodule that later grows into a solid or partially cystic tumor that is mobile over the underlying subcutaneous tissues. It can present ulceration, inflammation or even bleeding and can cause necrosis of the adjacent tissues.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018850
- UMLS:C2959585
- NCIT:C27125
Additional Mondo synonyms (9)
Pilar cyst · Pilar tumor · Pilar tumour · proliferating Pilar tumor · proliferating Pilar tumour · proliferating Tricholemmal tumor · proliferating Tricholemmal tumour · proliferating trichilemmal tumor · proliferating trichilemmal tumour
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
626 matched papers (303 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
626
626 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
626 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
303 in the last 10 years · high confidence · 85th percentile (publications denominator)
Phrase hits: 626 · MeSH hits: 0
Who's working on it?
899
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nijhawan RI4 papers · 2026
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: rajiv.nijhawan@utsouthwestern.edu.
Papers in Europe PMC - 02Zhang G4 papers · 2025
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200040, China.
Papers in Europe PMC - 03Chughtai A3 papers · 2023
Histopathology, Chughtai Institute of Pathology, Lahore, PAK.
Papers in Europe PMC - 04Hoang MP3 papers · 2025
Professor of Pathology, Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Papers in Europe PMC - 05Li Y3 papers · 2026
Pathology, LSU Health Shreveport, Shreveport, Louisiana, USA.
Papers in Europe PMC - 06Liao C3 papers · 2025
Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Papers in Europe PMC - 07Wang X3 papers · 2026
Department of Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Papers in Europe PMC - 08Wu M3 papers · 2025
Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Papers in Europe PMC - 09Abdelhammed MH2 papers · 2026
Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Papers in Europe PMC - 10Agarwal S2 papers · 2023
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Proliferating trichilemmal cyst" OR "Pilar cyst" OR "Pilar tumor" OR "Pilar tumour" OR "proliferating Pilar tumor" OR "proliferating Pilar tumour" OR "proliferating Tricholemmal tumor" OR "proliferating Tricholemmal tumour" OR "proliferating trichilemmal tumor" OR "proliferating trichilemmal tumour"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Proliferating trichilemmal cyst" OR "Pilar cyst" OR "Pilar tumor" OR "Pilar tumour" OR "proliferating Pilar tumor" OR "proliferating Pilar tumour" OR "proliferating Tricholemmal tumor" OR "proliferating Tricholemmal tumour" OR "proliferating trichilemmal tumor" OR "proliferating trichilemmal tumour"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:01:36.095Z